Application of a modified bioassay for monitoring serum teicoplanin and vancomycin in febrile neutropenic patients.
Teicoplanin is a glycopeptide antibiotic with a mode of action and spectrum of activity similar to those of vancomycin. Its efficacy and tolerability as empiric therapy and its pharmacokinetic properties in neutropenic patients are being studied in a double-blinded, randomized trial in comparison with those of vancomycin. We report here a modified agar diffusion bioassay which is suitable for monitoring levels of either teicoplanin or vancomycin in serum during combination therapy with beta-lactams, aminoglycosides, and amphotericin B. Serum samples spiked with either teicoplanin or vancomycin gave reproducible results (mean coefficient of variation, 8.8%) regardless of the presence of tobramycin, amikacin, piperacillin, ceftazidime, amphotericin B, or their combinations. Among 25 patients who received teicoplanin at a dosing schedule of 6 mg/kg every 24 h intravenously, steady state was reached after 14.2 +/- 4.0 days, and 1-h peak and trough concentrations of teicoplanin in serum at steady state were 40.8 +/- 15.0 and 12.5 +/- 3.2 mg/liter, respectively. In contrast, among 25 patients who received vancomycin at a dosing schedule of 15 mg/kg every 12 h intravenously, steady state was reached by 24 h, and the 1-h peak and trough concentrations in serum were 37.5 +/- 15.6 and 8.3 +/- 3.8 mg/liter, respectively. The elimination half-lives for teicoplanin estimated by two separate approaches agreed closely with each other: 80.5 +/- 21.5 h by an accumulation model (M. Gilbaldi and D. Perrier, Pharmacokinetics, 2nd ed., p. 121, 1982) and 87.3 +/- 19.3 h as predicted from the degree of renal function (M. Rowland, Clin. Pharmacokinetic 18:184-209, 1990). These values were 14- to 15-fold higher than that for vancomycin (5.6 +/- 1.8 h). Since considerable variability was noted in the pharmacokinetic parameters for both teicoplanin and vancomycin among the individual patients, our data further emphasized the need for frequent monitoring of these drugs during empiric therapy of the febrile neutropenic patient.
Kureishi
A
A
Department of Medicine, University of British Columbia, Vancouver, Canada.
Jewesson
P J
PJ
Bartlett
K H
KH
Cole
C D
CD
Chow
A W
AW
D000328:Adult; D000368:Aged; D000617:Aminoglycosides / Q000494:pharmacology; D000666:Amphotericin B / Q000494:pharmacology; D000900:Anti-Bacterial Agents / Q000097:blood* / Q000493:pharmacokinetics / Q000494:pharmacology; D004311:Double-Blind Method; D005260:Female; D005334:Fever / Q000097:blood* / Q000188:drug therapy; D006020:Glycopeptides / Q000097:blood / Q000493:pharmacokinetics; D006801:Humans; D007769:Lactams; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000097:blood* / Q000188:drug therapy; D015203:Reproducibility of Results; D017334:Teicoplanin; D014640:Vancomycin / Q000097:blood* / Q000493:pharmacokinetics
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D006020:Glycopeptides; D007769:Lactams; D017334:Teicoplanin; D014640:Vancomycin; D000666:Amphotericin B